1. Home
  2. BIVI vs NXPL Comparison

BIVI vs NXPL Comparison

Compare BIVI & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIVI
  • NXPL
  • Stock Information
  • Founded
  • BIVI 2013
  • NXPL 1997
  • Country
  • BIVI United States
  • NXPL United States
  • Employees
  • BIVI N/A
  • NXPL N/A
  • Industry
  • BIVI Biotechnology: Pharmaceutical Preparations
  • NXPL Telecommunications Equipment
  • Sector
  • BIVI Health Care
  • NXPL Telecommunications
  • Exchange
  • BIVI Nasdaq
  • NXPL Nasdaq
  • Market Cap
  • BIVI 15.0M
  • NXPL 17.9M
  • IPO Year
  • BIVI N/A
  • NXPL N/A
  • Fundamental
  • Price
  • BIVI $6.03
  • NXPL $0.69
  • Analyst Decision
  • BIVI
  • NXPL
  • Analyst Count
  • BIVI 0
  • NXPL 0
  • Target Price
  • BIVI N/A
  • NXPL N/A
  • AVG Volume (30 Days)
  • BIVI 66.5K
  • NXPL 57.1K
  • Earning Date
  • BIVI 09-29-2025
  • NXPL 08-13-2025
  • Dividend Yield
  • BIVI N/A
  • NXPL N/A
  • EPS Growth
  • BIVI N/A
  • NXPL N/A
  • EPS
  • BIVI N/A
  • NXPL N/A
  • Revenue
  • BIVI N/A
  • NXPL $62,515,000.00
  • Revenue This Year
  • BIVI N/A
  • NXPL N/A
  • Revenue Next Year
  • BIVI N/A
  • NXPL N/A
  • P/E Ratio
  • BIVI N/A
  • NXPL N/A
  • Revenue Growth
  • BIVI N/A
  • NXPL 19.36
  • 52 Week Low
  • BIVI $5.74
  • NXPL $0.43
  • 52 Week High
  • BIVI $75.00
  • NXPL $2.30
  • Technical
  • Relative Strength Index (RSI)
  • BIVI 34.02
  • NXPL 42.79
  • Support Level
  • BIVI $7.24
  • NXPL $0.72
  • Resistance Level
  • BIVI $7.75
  • NXPL $0.94
  • Average True Range (ATR)
  • BIVI 0.72
  • NXPL 0.07
  • MACD
  • BIVI -0.10
  • NXPL -0.02
  • Stochastic Oscillator
  • BIVI 8.78
  • NXPL 11.26

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

Share on Social Networks: